Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia
2013-04-12
(Press-News.org) April 11, 2013, Fort Lauderdale, Fla. -- Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH).
OIH refers to increased pain sensitivity due to high-dose or prolonged opioid exposure. Dexmedetomidine is an alpha-2 adrenergic agonist that is believed, based on prior research, to reduce pain and opioid requirements after surgery (Blaudszun et al, Anesthesiology 2012;116(6):1312-22). In the current study, OIH was induced by high doses of remifentanil, which is an ultra short-acting synthetic opioid used during surgery as an adjunct to anesthesia and to relieve pain.
"High-dose remifentanil can induce hyperalgesia, which is marked by a decreased mechanical hyperalgesia threshold, enhanced pain intensity, shorter time to first postoperative analgesic requirement and greater morphine consumption," said Kim Yeon-Dong, MD, lead study author and a clinical professor of anesthesiology and pain medicine at Wonkwang University Hospital in Iksan City, South Korea. "Dexmedetomidine infusion efficiently alleviated these symptoms."
Patients treated with dexmedetomidine reported less pain, used less post-surgical morphine, and went longer before requesting medication for pain relief than patients treated with placebo. They also reported fewer adverse opioid-related effects, including nausea.
The research was conducted on 90 patients who underwent laparoscopically-assisted vaginal hysterectomy. Patients were randomly assigned to 1 of 3 research groups, each of which received either dexmedetomidine or placebo saline 15 minutes before surgery. During surgery, all patients received a remifentanil infusion.
Group C received placebo and a comparatively low dose (0.05 µg/kg/min) of remifentanil. The next 2 groups received higher doses of remifentanil: group RH received placebo and 0.3 µg/kg/min remifentanil; and group DRH received dexmedetomidine and 0.3 µg/kg/min remifentanil.
Patients in the RH group, who were treated with placebo and high-dose remifentanil, had a lower threshold for mechanical hyperalgesia in the 24 hours after surgery than the other 2 groups and were the first to require analgesia for pain. The same placebo group also had more pain intensity and greater use of patient-controlled morphine for pain than group DRH, which received dexmedetomidine and high-dose remifentanil. Additionally, group DRH reported less shivering and postoperative nausea and vomiting than the other 2 groups. All findings were statistically significant.
Dr. Kim said those who might benefit from treatment with alpha-2 agonists include patients who are hospitalized for painful conditions or procedures and who have not responded to traditional opioid medication.
Poster 117 - Antihyperalgesic Effects of Dexmedetomidine on High-dose Remifentanil-induced Hyperalgesia
###
About AAPM
The American Academy of Pain Medicine is the premiere 2,400-member medical association for pain physicians and their treatment teams. Now in its 30th year of service, the Academy's mission is to optimize the health of patients in pain and eliminate it as a major public health problem by advancing the practice and specialty of pain medicine through education, training, advocacy and research. Information is available on the Academy's website at http://www.painmed.org.
END
ELSE PRESS RELEASES FROM THIS DATE:
2013-04-12
Berlin, Germany: People with sleep apnoea are more likely to fail a driving simulator test and report nodding whilst driving, according to new research.
The study will be presented today (12 April 2013) at the Sleep and Breathing Conference in Berlin, organised by the European Respiratory Society and the European Sleep Research Society.
Sleep apnoea has previously been linked with an increased chance of being involved road traffic accidents. A research team from the University Hospital in Leeds, UK, carried out two separate studies looking at the effect sleep apnoea ...
2013-04-12
Highlights
There is substantial regional variation in the magnitude of racial differences in end-of-life care among US adults with kidney failure.
Black-white differences in dialysis discontinuation and hospice referral are most pronounced in regions with the highest levels of end-of-life spending.
More than 590,000 Americans in 2010 were treated for kidney failure.
Washington, DC (April 11, 2013) — At the end of life, black patients with kidney failure receiving chronic dialysis are less likely to be referred to hospice and to discontinue dialysis compared with ...
2013-04-12
Highlights
People with apple-shaped bodies tend to have lower kidney function, lower kidney blood flow, and higher blood pressure within the kidneys than people with pear-shaped bodies.
The findings may help explain why people with apple-shaped bodies are more likely than those with pear-shaped bodies to develop kidney disease.
Washington, DC (April 11, 2013) — High blood pressure in the kidneys of people with apple-shaped bodies may be responsible for their increased risk of developing kidney disease later in life, according to a study appearing in an upcoming issue ...
2013-04-12
LA JOLLA, CA – April 11, 2013 – Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C.
The study, reported in the April 12, 2013 issue of the journal Science, focused on the activity of the body's type 1 interferon (IFN-I) proteins. Since its discovery over 50 years ago, IFN-I has been believed to be an especially powerful antiviral agent that marshals the immune system's response against the body's foreign ...
2013-04-12
CHAMPAIGN, Ill. — A new class of tiny, injectable LEDs is illuminating the deep mysteries of the brain.
Researchers at the University of Illinois at Urbana-Champaign and Washington University in St. Louis developed ultrathin, flexible optoelectronic devices – including LEDs the size of individual neurons – that are lighting the way for neuroscientists in the field of optogenetics and beyond.
Led by John A. Rogers, the Swanlund professor of materials science and engineering at the U. of I., and Michael R. Bruchas, a professor of anesthesiology at Washington University, ...
2013-04-12
April 11, 2013, Fort Lauderdale, Fla. -- Researchers from Virginia Commonwealth University (VCU) sought to shed light on the biopsychosocial and spiritual effects of taking prescribed opioids to treat noncancer pain. Such questions have received little examination and impact the challenging decision of when and how to use opioids, the study authors wrote in a scientific poster presented today at the 29th Annual Meeting of the American Academy of Pain Medicine. They found that taking opioids had many and diverse consequences for patients in terms of biological, psychological, ...
2013-04-12
April 11, 2013, Fort Lauderdale, Fla. -- Veterans who sustained major limb injuries during combat reported little improvement in symptoms of depression, anxiety, post-traumatic stress disorder (PTSD) and other mental-health problems up to 2 years post injury, according to research presented today. In contrast, pain showed the most improvement 3-6 months after acute hospitalization, and then leveled off after 1 year. The investigative team, led by Rollin M. Gallagher, MD, MPH, reported results during a poster session at the 29th Annual Meeting of the American Academy of ...
2013-04-12
April 11, 2013, Fort Lauderdale, Fla. -- A new study suggests that the type of bio-cellular grafts increasingly used by surgeons to repair damaged tissue may be useful for treating low-back pain (LBP). However, not all sufferers responded equally to the novel therapy. Results reported today at the 29th Annual Meeting of the American Academy of Pain Medicine ranged from complete pain relief to no improvement.
The procedure involved injecting a concentrated form of bone-marrow cellular aspirate into lumbar discs in patients with clinical and objective evidence of disc ...
2013-04-12
April 11, 2013, Fort Lauderdale, Fla. -- Half of patients on high-dose, long-term opioid therapy had hormonal disturbances or signs of inflammation, while 100 percent reported improved pain control and mental outlook, new research shows. The results, reported today at the 29th Annual Meeting of the American Academy of Pain Medicine, present rare data on the effects of opioids beyond 10 years. Most clinical trials that examine opioid use are of short duration, and little is known about long-term outcomes, particularly in patients who suffer from noncancer pain.
The 40 ...
2013-04-12
April 11, 2013, Fort Lauderdale, Fla. -- Changing the parameters used to deliver radiofrequency (RF) treatment greatly affects the size of the resulting heat lesion, researchers reported today in a study expected to deliver greater precision and more treatment options in interventional pain management. Results were presented at the 29th Annual Meeting of the American Academy of Pain Medicine.
"This is the most comprehensive study of radiofrequency heat lesion size for pain management to date," said the study's lead author, Eric Cosman Jr., PhD, scientific director of ...
LAST 30 PRESS RELEASES:
[Press-News.org] Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia
